newsfilter
← Latest News
GlobeNewswire·

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

  • Addex Therapeutics announced new preclinical data published in the International Journal of Neuropsychopharmacology regarding ADX71743, a selective negative allosteric modulator of mGlu7.
  • The research demonstrates that ADX71743 increases wakefulness while reducing REM & non-REM sleep in rats.
  • The compound altered stress-induced changes in glutamate, GABA, & monoamines across multiple brain regions in awake animals.
  • These findings validate the pharmacological profile of mGlu7 inhibition & support its potential as a therapeutic target for mood disorders, anxiety, PTSD, & dysregulated stress responses.
  • ADX71743 is a brain-penetrant molecule discovered by Addex & is now advanced by Neurosterix, a neuroscience company launched by Addex & Perceptive Advisors in 2024.
  • Previous studies indicate mGlu7 inhibition can modulate anxiety behaviors, disrupt fear memory reconsolidation, & influence glutamatergic signaling.
  • Addex holds a 20% equity interest in Neurosterix US Holdings LLC, which is developing mGlu7 NAM programs for mood disorders.
  • Addex's lead candidate dipraglurant is under evaluation for brain injury recovery, while independent GABAB PAM programs target chronic cough.